Research progress in tumor-targeted masked antibodies
10.3867/j.issn.1000-3002.2025.01.006
- VernacularTitle:肿瘤靶向性遮蔽抗体研究进展
- Author:
Jianping ZOU
1
;
Xinxin YAO
1
;
Chun WEN
1
;
Shan ZHU
1
;
Shihui ZHANG
1
;
Xiaojing ZHANG
1
Author Information
1. 赣南医科大学赣南创新与转化医学研究院,重大疾病新药靶发现及新药创制全国重点实验室,江西 赣州 341000
- Publication Type:Journal Article
- Keywords:
tumors;
tumor-targeted therapy;
masked antibody;
tumor microenvironment;
tumor-associated protease
- From:
Chinese Journal of Pharmacology and Toxicology
2025;39(1):58-68
- CountryChina
- Language:Chinese
-
Abstract:
Antibody-based therapies are one of the crucial tumor-targeted therapies,enabling pre-cise elimination of tumor cells by specifically binding to antigens on the tumor cell surface.However,their wide applications in solid tumor therapy are often limited by on-target toxicity.Recent advance-ments in antibody engineering have led to the development of novel tumor-targeted masking antibod-ies,which are specifically designed to address these limitations.Masking antibodies typically consist of an antibody domain,a masking domain and a linker.These antibodies are characterized by selective activation and other functional properties.Currently,various masking antibody technologies with distinct characteristics have been developed and have demonstrated favorable safety profiles in animal studies.This review summarizes the structure and characteristics of tumor-targeted masking antibodies outlines common masking technologies and their drug development in order to offer new lines of thought for the design and development of next-generation tumor-targeted therapeutics.
